ARID1A deficiency in EBV-positive gastric cancer is partially regulated by EBV-encoded miRNAs, but not by DNA promotor hypermethylation
- 16 November 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Carcinogenesis
- Vol. 42 (1) , 21-30
Abstract
AT-rich interactive domain 1A (ARID1A), which is a tumor suppressor gene, is frequently mutated in Epstein-Barr virus-positive gastric cancer [EBV (+) GC]. While most ARID1A mutations in GC are truncating mutations, leading to loss of ARID1A protein expression, epigenetic modifications appear to contribute to ARID1A deficiency in EBV (+) GC harboring wild-type ARID1A. Based on the significant role of epigenetic modifications in EBV (+) GC that contributes to ARID1A deficiency, the methylation status of ARID1A was evaluated in EBV-infected cells and GC patients using a publicly available microarray and the Cancer Genome Atlas (TCGA) database. EBV-encoded miRNAs that potentially target ARID1A were identified as an additional epigenetic modulator by computational prediction. In vitro experiments were conducted to evaluate how EBV-encoded miRNAs affected ARID1A mRNA and protein levels. In clinical GC samples, the expression of predicted miRNAs and ARID1A and the mutation status of ARID1A was evaluated. As results, ARID1A was not hypermethylated in EBV (+) GC samples or EBV-infected GC cells. EBV infection did not alter ARID1A mRNA levels, suggesting that ARID1A protein deficiency was caused by post-transcriptional gene silencing in ARID1A-WT EBV (+) GC. Overexpression of miR-BART11-3p and miR-BART12, which were identified as miRNAs that potentially bind ARID1A, suppressed ARID1A protein expression in MKN7 and NCI-N87 cells. Highly expressed miR-BART11-3p and miR-BART12 were correlated with decreased ARID1A levels in GC tumors which did not harbor ARID1A mutations. The present findings revealed that ARID1A expression was epigenetically regulated by miR-BART11-3p and miR-BART12 in EBV (+) GC.Keywords
Funding Information
- Japan Society for the Promotion of Science (18K08652, 19K09099, 20H03695)
- National Cancer Center Research and Development Fund
This publication has 38 references indexed in Scilit:
- Recent progress in the study of methylated tumor suppressor genes in gastric cancerChinese Journal of Cancer, 2013
- Epstein–Barr Virus Infection as an Epigenetic Driver of TumorigenesisCancer Research, 2012
- Classification of Epstein–Barr Virus–Positive Gastric Cancers by Definition of DNA Methylation EpigenotypesCancer Research, 2011
- Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancerNature Genetics, 2011
- The Association of MicroRNA Expression with Prognosis and Progression in Early-Stage, Non–Small Cell Lung Adenocarcinoma: A Retrospective Analysis of Three CohortsClinical Cancer Research, 2011
- The microRNAs of Epstein–Barr Virus are expressed at dramatically differing levels among cell linesVirology, 2009
- Epigenetics in CancerNew England Journal of Medicine, 2008
- Cancer epigenomics: DNA methylomes and histone-modification mapsNature Reviews Genetics, 2007
- Expression of Viral MicroRNAs in Epstein-Barr Virus-Associated Gastric CarcinomaJournal of Virology, 2007
- Epstein-Barr Virus-Positive Gastric Carcinoma Demonstrates Frequent Aberrant Methylation of Multiple Genes and Constitutes CpG Island Methylator Phenotype-Positive Gastric CarcinomaThe American Journal of Pathology, 2002